YU49995A - Polinukleotidna vakcina za virus herpesa - Google Patents

Polinukleotidna vakcina za virus herpesa

Info

Publication number
YU49995A
YU49995A YU49995A YU49995A YU49995A YU 49995 A YU49995 A YU 49995A YU 49995 A YU49995 A YU 49995A YU 49995 A YU49995 A YU 49995A YU 49995 A YU49995 A YU 49995A
Authority
YU
Yugoslavia
Prior art keywords
hsv
pnv
immunization
animals
herpes virus
Prior art date
Application number
YU49995A
Other languages
English (en)
Inventor
M.E. Amstrong
R.D. Keys
M.A. Lewis
M.A. Liu
W.L. Mc CLEMENTS
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of YU49995A publication Critical patent/YU49995A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

POLINUKLEOTIDNA VAKCINA ZA VIRUS HERPESA - Geni koji kodiraju proteine herpes simpleks virusa tipa 2 (HSV-2) se kloniraju u eukariotične ekspresione vaktore da bi ekspresionisali kodirane proteine in vivo i mišićne delije sisara. Životinje se imuniziraju injekcijom ovih DNK konstrukcija, nazvanih polinukleotidne vakcine ili PNV, u njihove mi'Side. U DNK titraciji nadeno je da jedna imunizacija od. 0.5 "F128M".m"F255D".g fledne PNV daje 90% serokonverzije za deset nedelja posle imunizacije. Imuni antiserumi neutralist i HSV-2 i HSV-1 u ćelijskoj kulturi. Kad se životinje izazovu sa HSV-2 postignuta je značajna (p .001) zaštita od letalne infekcije posle PNV vakcinacije.
YU49995A 1994-07-22 1995-07-21 Polinukleotidna vakcina za virus herpesa YU49995A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27945994A 1994-07-22 1994-07-22

Publications (1)

Publication Number Publication Date
YU49995A true YU49995A (sh) 1998-05-15

Family

ID=23069059

Family Applications (1)

Application Number Title Priority Date Filing Date
YU49995A YU49995A (sh) 1994-07-22 1995-07-21 Polinukleotidna vakcina za virus herpesa

Country Status (10)

Country Link
EP (1) EP0772680A1 (sh)
JP (1) JPH10503649A (sh)
AU (1) AU708460B2 (sh)
CA (1) CA2195099A1 (sh)
CO (1) CO4410257A1 (sh)
HR (1) HRP950412A2 (sh)
IL (1) IL114576A0 (sh)
WO (1) WO1996003510A1 (sh)
YU (1) YU49995A (sh)
ZA (1) ZA956106B (sh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
AU738835B2 (en) * 1994-07-22 2001-09-27 Merck & Co., Inc. A polynucleotide herpes virus vaccine
US7094767B2 (en) 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
CA2267645A1 (en) * 1996-10-01 1998-04-09 Merck & Co., Inc. A polynucleotide herpes virus vaccine
JP2001503257A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド Ｉｌ―１２遺伝子発現および送達系および使用
AU4908197A (en) * 1996-10-18 1998-05-15 Valentis, Inc. Gene expression and delivery systems and uses
GB9720633D0 (en) * 1997-09-29 1997-11-26 Univ Bristol BHV-2 vector
JP2002502884A (ja) * 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー インターロイキン−１２および単純ヘルペスウイルス抗原を含んでなるワクチン
US6867000B2 (en) * 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
US9012349B1 (en) 2013-11-01 2015-04-21 Ut-Battelle Llc Method of synthesizing bulk transition metal carbide, nitride and phosphide catalysts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751664T2 (de) * 1986-08-01 1996-06-05 Commw Scient Ind Res Org Rekombinanter impfstoff
ATE240401T1 (de) * 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
ATE123065T1 (de) * 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd Proteine und deren herstellung.

Also Published As

Publication number Publication date
JPH10503649A (ja) 1998-04-07
WO1996003510A1 (en) 1996-02-08
AU708460B2 (en) 1999-08-05
IL114576A0 (en) 1995-11-27
ZA956106B (en) 1996-04-10
HRP950412A2 (en) 1997-10-31
CA2195099A1 (en) 1996-02-08
CO4410257A1 (es) 1997-01-09
AU3101295A (en) 1996-02-22
EP0772680A1 (en) 1997-05-14

Similar Documents

Publication Publication Date Title
AU734442B2 (en) Polynucleotide vaccine formula in particular against bovine respiratory pathology
ATE85622T1 (de) Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
CN110269932A (zh) 非洲猪瘟病毒疫苗及其用途
DK1030690T3 (da) Rekombinante vacciner, der omfatter immunogene svækkede bakterier med RpoS positiv fænotype
GR3017535T3 (en) Live vaccines.
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
BR9205771A (pt) Vetor de vírus recombinantes e processo para a fabricaçao do mesmo
YU49995A (sh) Polinukleotidna vakcina za virus herpesa
KR970009347B1 (en) Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
EP0192902A2 (en) DNA sequences from Varicella-zoster virus, vectors and hosts containing them, the corresponding polypeptides and the compositions containing them
ATE173166T1 (de) Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
UA40571C2 (uk) Мутант коров'ячого вірусу герпесу типу 1 (bhv-1), композиція вакцини для вакцинації тварин для захисту їх від bhv-1, композиція вакцини для вакцинації тварин для захисту їх від патогена
US5718902A (en) Double recombinant vaccinia virus vaccines
HK51597A (en) Vaccines for human respiratory virus
EP0294469A4 (en) VACCINES AND DIAGNOSTIC ANALYSIS FOR HAEMOPHILUS INFLUENZAE.
ZA918876B (en) Avirulent microbes and uses therefor:salmonella typhi
CN102089423A (zh) 通过表达ⅰ型干扰素反应的抑制剂来增强来自基于病毒的疫苗载体的转基因表达
DE69030099T2 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
ES8504254A1 (es) Procedimiento para obtener un polipeptido
DE69332264D1 (de) Mutanten des infektiösen rinder rhinotracheitis-virus und impfstoffe
ES2322236T3 (es) Mutantes del ehv gm-negativos.
Castrucci et al. Immunization against bovine herpesvirus-1 infection. Preliminary tests in calves with a DNA vaccine
CN102772793A (zh) 一种布鲁氏菌dna疫苗及其构建方法与应用
AU1853995A (en) Vaccine compositions
Amann et al. High-level production in Escherichia coli of hybrid proteins expressing parts of coding sequences of HSV glycoproteins.